Recombinant Human NOV/CCN3 Protein, CF | R&D Systems 1640-NV-050 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human NOV/CCN3 Protein, CF

catalog :

1640-NV-050

quantity :

50 ug

price :

400 USD

citations: 7

Reference
Son S, Kim H, Lim H, Lee J, Lee K, Shin I. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. Cell Death Dis. 2023;14:81 pubmed publisher
Gupta R, Turati V, Brian D, Thrussel C, Wilbourn B, May G, et al. Nov/CCN3 Enhances Cord Blood Engraftment by Rapidly Recruiting Latent Human Stem Cell Activity. Cell Stem Cell. 2020;26:527-541.e8 pubmed publisher
Kolb A, Shupp A, Mukhopadhyay D, Marini F, Bussard K. Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 2019;21:31 pubmed publisher
van Roeyen C, Boor P, Borkham Kamphorst E, Rong S, Kunter U, Martin I, et al. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects. Am J Pathol. 2012;180:1979-90 pubmed publisher
Zhang Y, Wang C. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. Oncogene. 2011;30:3549-62 pubmed publisher
Sin W, Tse M, Planque N, Perbal B, Lampe P, Naus C. Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J Biol Chem. 2009;284:29935-44 pubmed publisher
Riser B, Najmabadi F, Perbal B, Peterson D, Rambow J, Riser M, et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol. 2009;174:1725-34 pubmed publisher

product information

master code :

1640-NV

SKU :

1640-NV-050

product name :

Recombinant Human NOV/CCN3 Protein, CF

unit size :

50 ug

description :

The Recombinant Human NOV/CCN3 Protein, CF from R&D Systems is derived from NS0. The Recombinant Human NOV/CCN3 Protein, CF has been validated for the following applications: Bioactivity.

target :

NOV/CCN3

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

species :

Human

observed molecular weight :

48-60 kDa, reducing conditions

theoretical molecular weight :

37.1 kDa

gene symbol :

NOV

details of functionality :

Measured by its ability to mediate Balb/3T3 mouse embryonic fibroblast cell adhesion. Ball, D.K. etáal . (2003) Reproduction 125 :271. rhNOV, immobilized at 10 ╡g/mL, 100 ╡L/well, will mediate 30% Balbc/3T3 cell adhesion (3 x 104 cells/well added).

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

P48745

applications :

Bioactivity

source long :

Mouse myeloma cell line, NS0-derived human NOV/CCN3 protein Thr32-Met357, with a C-terminal 10-His tag

source short :

NS0

USD :

400 USD

alt names :

CCN family member 3, CCN3, CCN3IGF-binding protein 9, IBP-9, IGFBP-9, IGFBP9novH, Insulin-like growth factor-binding protein 9, nephroblastoma overexpressed gene, Nephroblastoma-overexpressed gene protein homolog, NOVH, protein NOV homolog

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.